Overview

A Prospective, Single-arm Clinical Trial of Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of adult patients who are predicted to have a high risk for developing severe acute graft-versus-host disease (aGVHD) by the daGOAT model.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital